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Pseudomonas aeruginosa bloodstream infection is a serious infection with significant patient mortality and
health-care costs. Nevertheless, the relationship between initial appropriate antimicrobial treatment and
clinical outcomes is not well established. This study was a retrospective cohort analysis employing automated
patient medical records and the pharmacy database at Barnes-Jewish Hospital. Three hundred five patients
with P. aeruginosa bloodstream infection were identified over a 6-year period (January 1997 through December
2002). Sixty-four (21.0%) patients died during hospitalization. Hospital mortality was statistically greater for
patients receiving inappropriate initial antimicrobial treatment (n  75) compared to appropriate initial
treatment (n  230) (30.7% versus 17.8%; P  0.018). Multiple logistic regression analysis identified inap-
propriate initial antimicrobial treatment (adjusted odds ratio [AOR], 2.04; 95% confidence interval [CI], 1.42
to 2.92; P  0.048), respiratory failure (AOR, 5.18; 95% CI, 3.30 to 8.13; P < 0.001), and circulatory shock
(AOR, 4.00; 95% CI, 2.71 to 5.91; P < 0.001) as independent determinants of hospital mortality. Appropriate
initial antimicrobial treatment was administered statistically more often among patients receiving empirical
combination antimicrobial treatment for gram-negative bacteria compared to empirical monotherapy (79.4%
versus 65.5%; P  0.011). Inappropriate initial empirical antimicrobial treatment is associated with greater
hospital mortality among patients with P. aeruginosa bloodstream infection. Inappropriate antimicrobial
treatment of P. aeruginosa bloodstream infections may be minimized by increased use of combination antimi-
crobial treatment until susceptibility results become known.
Bacterial bloodstream infections are serious infections asso-
ciated with significant mortality and health-care costs (36). In
many hospitals, Pseudomonas aeruginosa has become the most
common gram-negative bacterial species associated with seri-
ous hospital-acquired infections, particularly within intensive
care units (24, 29, 33). The hospital mortality associated with P.
aeruginosa bloodstream infections is reported to be greater
than 20% in most series and is highest among patients receiv-
ing inappropriate initial antimicrobial treatment (4, 6, 25, 32,
37). Unfortunately, prior studies of P. aeruginosa bloodstream
infection varied in how they defined appropriate antimicrobial
therapy and did not specifically examine the influence of ad-
ministering combination antimicrobial agents as a determinant
of appropriate treatment. Additionally, two recent meta-anal-
yses recommend the use of monotherapy with a beta-lactam
antibiotic for the empirical treatment of neutropenic fever and
severe sepsis, infections where P. aeruginosa is often an impor-
tant pathogen (26, 27).
Due to the clinical importance of bloodstream infections
due to P. aeruginosa, we performed a retrospective cohort
analysis with two main goals. First, we wanted to determine
whether the administration of appropriate initial antimicrobial
treatment was associated with better clinical outcomes for P.
aeruginosa bloodstream infections. Our second goal was to
examine the relationship between the empirical administration
of combination gram-negative antimicrobial therapy and ap-
propriate treatment for P. aeruginosa bloodstream infections.
MATERIALS AND METHODS
Study location and patients. This study was conducted at a university-affili-
ated, urban teaching hospital, Barnes-Jewish Hospital (1,200 beds). During a
6-year period (January 1997 to December 2002), all hospitalized patients with a
positive blood culture for P. aeruginosa were eligible for this investigation. This
study was approved by the Washington University School of Medicine Human
Studies Committee.
Study design and data collection. A retrospective cohort study design was
employed with the main outcome measure being hospital mortality. We also
assessed secondary outcomes, including the administration of appropriate initial
antimicrobial treatment, length of hospitalization, and the occurrence of persis-
tent bacteremia due to P. aeruginosa.
For all study patients the following characteristics were recorded by one of the
investigators (S. T. Micek, A. E. Lloyd, or R. M. Reichley): age, gender, race,
severity of illness based on the simplified acute physiology (SAP) score (21) and
the all patient refined diagnosis related group (APR-DRG) score (30), the
presence of underlying malignancy, neutropenia, infection source, and patient
location at the time of infection. Specific processes of medical care examined
during patients’ hospital stays included mechanical ventilation for respiratory
failure and the administration of vasopressors for circulatory shock. Variables
describing the bloodstream infections and their treatment were also recorded,
including administration of combination antimicrobials for gram-negative bac-
teria versus monotherapy and the appropriateness of initial antibiotic treatment.
All patient-level data were recorded from automated patient medical records
(EMTEK Health Care Systems Inc., Tempe, Ariz., and Clinical Desktop, BJC
Healthcare, St. Louis, Mo.) and the Barnes-Jewish Hospital Pharmacy auto-
mated database, all of which contain prospectively entered information.
* Corresponding author. Mailing address: Washington University
School of Medicine, 660 South Euclid Ave., Campus Box 8052, St.
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A computerized list of patients with a positive blood culture was generated
daily by the Microbiology Laboratory at Barnes-Jewish Hospital, which allowed
identification of potential study patients. Patients could be entered into the study
more than once only if the subsequent episode of P. aeruginosa bacteremia
occurred during a new hospital admission and at least 30 days had elapsed
between positive blood cultures for P. aeruginosa (5).
Definitions. All definitions were selected prospectively as part of the original
study design. We calculated SAP scores on the basis of clinical data available
from the first 24-h period following identification of a positive blood culture (21).
The APR-DRG was also employed to measure severity of illness, using a pro-
prietary method (1, 30). APR-DRGs include four severity-of-illness classes (mi-
nor, moderate, major, and extreme) within each DRG, assigned according to a
clinical algorithm evaluating multiple comorbidities, age, procedures, and prin-
cipal diagnoses (1).
The antimicrobial guidelines for Barnes-Jewish Hospital during the study
period recommended empirical treatment of suspected hospital-acquired blood-
stream infections with a combination of an antistaphylococcal drug (vancomycin
for methicillin-resistant staphylococci) and at least one antibiotic, usually a
beta-lactam, with gram-negative activity. For patients at increased risk for infec-
tion with antibiotic-resistant gram-negative bacteria (e.g., P. aeruginosa and Acin-
etobacter species), two antibiotics directed against gram-negative bacteria were
initially recommended (an antipseudomonal beta-lactam or a carbapenem in
combination with an aminoglycoside or a fluoroquinolone). The Barnes-Jewish
Hospital formulary promoted the use of ceftazidime up to 1997 and thereafter
cefepime as the primary antipseudomonal beta-lactam antibiotic. Imipenem and
ciprofloxacin were the formulary carbapenem and fluoroquinolone antibiotics,
respectively, available for clinical use during the entire study period. The anti-
biotic guidelines recommended modifying the initially prescribed empirical an-
timicrobial regimens based on the results of clinical cultures and the antimicro-
bial susceptibility of the identified pathogens. De-escalation or narrowing of the
initial empirically prescribed antimicrobial regimens was monitored by hospital
pharmacists and had to be approved by the patient’s primary physician team (2,
16).
For purposes of this investigation, inappropriate antimicrobial treatment of a
bloodstream infection was defined as the microbiological documentation of in-
fection (i.e., a positive blood culture result) that was not effectively treated at the
time the causative microorganism and its antibiotic susceptibility were known
(15, 17, 19). The microbiology laboratory performed antimicrobial susceptibility
testing of clinical isolates by the Kirby-Bauer disk diffusion method according to
guidelines and breakpoints established by the National Committee for Clinical
Laboratory Standards (23), using 150-mm round plates of Mueller-Hinton agar
(BBL, Becton-Dickinson, Cockeysville, Md.). A technologist experienced in
reading zones of inhibition with a ruler against a black background measured the
zone diameters manually. Inappropriate antimicrobial treatment included the
absence of gram-negative antimicrobial agents with in vitro activity against P.
aeruginosa and the administration of gram-negative antimicrobial agents to
which the P. aeruginosa isolates were resistant based on susceptibility testing.
Circulatory shock was defined as systolic arterial pressure lower than 90 mm
Hg for at least 1 h despite adequate fluid replacement and more than 5 g of
dopamine/kg of body weight or current treatment with epinephrine or norepi-
nephrine (25). Additionally, urinary output of less than 0.5 ml/kg of body weight
for at least 1 h was required for circulatory shock. Respiratory failure was defined
as the need for mechanical ventilation applied by either an endotracheal tube or
by mask.
Blood culture technique. Blood cultures were obtained from two peripheral
sites by nurses or hospital-trained phlebotomists. Before collecting the blood
cultures, skin was disinfected with 70% isopropyl alcohol followed by 2% iodine
tincture. The antecubital fossae were the preferred sampling sites, using sterile
needles and syringes. When only one peripheral site was available and the patient
had a central vein catheter in place, the second blood culture sample was
obtained from the central vein catheter. Injection of 5 ml or less of blood into a
blood culture bottle was not permitted, to avoid false-negative results (35). All
blood samples were inoculated into aerobic medium and processed using the
BACTEC blood culture system (Becton Dickinson, Sparks, Md.).
Statistical analysis. All comparisons were unpaired, and all tests of signifi-
cance were two-tailed. Continuous variables were compared using the Student t
test for normally distributed variables and the Mann-Whitney U test for non-
normally distributed variables. The chi-square or Fisher’s exact test was used to
compare categorical variables. The primary data analysis compared hospital
nonsurvivors with survivors. Values are expressed as the mean  standard de-
viation (continuous variables) or as a percentage of the group from which they
were derived (categorical variables). All P values were two-tailed, and P values of
0.05 or less were considered to indicate statistical significance.
We performed multiple logistic regression analysis using SPSS, version 11.0 for
Windows (SPSS, Inc., Chicago, Ill.). Multivariate analysis was performed using
models that were judged a priori to be clinically sound (7). This was prospectively
determined to be necessary to avoid producing spuriously significant results with
multiple comparisons. All potential risk factors significant at the 0.2 level were
entered into the model. A stepwise approach was used to enter new terms into
the logistic regression model, where hospital mortality was the dependent out-
come variable and 0.05 was set as the limit for the acceptance or removal of new
terms.
RESULTS
Patients. A total of 596 consecutive patients with blood-
stream infection due to P. aeruginosa were evaluated. Two
hundred twenty-four (37.6%) patients were excluded from
analysis due to the presence of polymicrobial bloodstream
infection. Sixty-seven (11.2%) patients, with a hospital mortal-
ity of 55.2%, were excluded due to incomplete information
regarding antimicrobial treatment during the first 24 h follow-
ing the collection of blood cultures. The remaining 305 pa-
tients constituted the study cohort. The mean age of the pa-
tients was 58.2  17.8 years (range, 16 to 97 years), and the
mean SAP score was 11.5  4.9 (range, 3 to 26). There were
173 (56.7%) men and 132 (43.3%) women; 216 (70.8%) pa-
tients were white, 79 (25.9%) were black, and 10 (3.3%) were
either Hispanic or Asian American.
Patient characteristics according to hospital mortality. Hos-
pital nonsurvivors were statistically more likely to be in an
intensive care unit setting at the time the bloodstream infec-
tion was diagnosed, to have the lung identified as the source of
P. aeruginosa bloodstream infection, and to have greater SAP
scores and APR-DRG scores (Table 1). Additionally, hospital
nonsurvivors statistically more often required vasopressors for
circulatory shock and mechanical ventilation for respiratory
failure and developed acute renal failure (Table 2).
Antimicrobial treatment characteristics. The antimicrobial
susceptibilities of the P. aeruginosa bloodstream isolates ob-
tained during the study period are presented in Table 3. Sev-
TABLE 1. Baseline characteristics of patients at admission and
infection sourcea
Variable Survivors(n  241)
Nonsurvivors
(n  64) P value
Age (yrs) 58.8  17.9 56.0  17.4 0.256
Male gender, n (%) 134 (55.6) 39 (60.9) 0.444
Race, n (%)
White 164 (68.0) 52 (81.3) 0.114
African American 68 (28.2) 11 (17.2)
Other 9 (3.7) 1 (1.6)
Neutropenia, n (%) 54 (22.4) 12 (18.8) 0.528
Underlying malignancy, n (%) 100 (41.5) 26 (40.6) 0.900
Patient location, n (%)
Intensive care unit 116 (48.1) 52 (81.3) 0.001
Hospital ward 116 (48.1) 11 (17.2)
Other 9 (3.7) 1 (1.6)
SAP score 10.9  4.6 13.8  5.2 0.007
APR-DRG score 3.3 0.7 3.9  0.4 0.001
Infection source, n (%)
Lung 42 (17.4) 24 (37.5) 0.005
Urinary tract 49 (20.3) 7 (10.9)
Soft tissue or wound 31 (12.9) 8 (12.5)
Unknown 119 (49.4) 25 (39.1)
a Values presented are means  standard deviations.
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enty-five (24.6%) patients were treated with inappropriate ini-
tial antimicrobial regimens for P. aeruginosa bloodstream
infections. Nine (12.0%) patients treated with inappropriate
initial antimicrobial regimens received no initial gram-negative
antibiotics directed against P. aeruginosa. Sixty-six (88.0%) pa-
tients receiving inappropriate therapy were treated with anti-
biotics having recognized activity against P. aeruginosa but for
which the isolated bacteria were actually resistant by in vitro
susceptibility testing. Patients receiving inappropriate initial
antimicrobial treatment had statistically greater APR-DRG
scores (3.6  0.6 versus 3.3  0.7; P  0.014) and statistically
lower rates of neutropenia (5.3% versus 27.0%; P 0.001) and
underlying malignancy (30.7% versus 44.8%; P  0.031) com-
pared to patients receiving appropriate initial antimicrobial
treatment.
Hospital mortality was statistically greater for patients re-
ceiving inappropriate initial antimicrobial treatment (n  75)
compared to appropriate initial treatment (n  230) (30.7%
versus 17.8%; P  0.018). Twenty-nine patients (9.5%) had
inappropriate treatment administered beyond 24 h from initial
antimicrobial treatment but for less than 48 h before changing
to appropriate antimicrobials. These patients had similar hos-
pital mortality to patients receiving appropriate treatment be-
tween 24 and 48 h after the start of antibiotics (n  276)
(20.7% versus 19.2%; P was not significant). Three patients
received inappropriate antimicrobial treatment beyond 48 h
(100% hospital survival). Inappropriate initial antimicrobial
administration was statistically more likely to occur among
patients receiving monotherapy directed against gram-negative
bacteria compared to those receiving combination therapy
(34.5% versus 20.6%; P  0.011). Treatment with ceftazidime
or cefepime was statistically greater among patients receiving
appropriate initial antimicrobial treatment, while the initial
empirical administration of ciprofloxacin was statistically
greater among patients receiving inappropriate treatment (Ta-
ble 4).
Among patients receiving appropriate initial empirical anti-
microbial treatment with a single beta-lactam (n  95; mor-
tality  12.6%), a single aminoglycoside (n  29; mortality 
10.3%), the combination of a beta-lactam and an aminoglyco-
side (n  59; mortality  22.0%), or ciprofloxacin alone (n 
15; mortality  6.7%), there was no statistical difference in
hospital mortality (P  0.214). Similarly, for appropriate de-
finitive antimicrobial treatment there was no statistical differ-
ence in hospital mortality among patients receiving a single
beta-lactam (n  92; mortality  15.2%), the combination of a
beta-lactam and an aminoglycoside (n  59; mortality 
22.0%), or ciprofloxacin alone (n  14; mortality  14.3%) (P
 0.312). APR-DRG scores (12.1  4.8 versus 10.4  5.0: P 
0.091) and SAP scores (3.4  0.7 versus 3.2  0.8; P  0.175)
were not statistically different among patients receiving com-
bination antimicrobial therapy directed against P. aeruginosa
compared to monotherapy.
Multivariate analysis. Multiple logistic regression analysis
identified the administration of inappropriate initial antimicro-
bial treatment, respiratory failure, and circulatory shock as
independent determinants of hospital mortality (Table 5). The
APR-DRG scores were not entered into the multivariate anal-
ysis because no other variables achieved statistical significance
with this variable in the model. All other combinations of
variables entered into the logistic regression analysis yielded a
final model with inappropriate initial antimicrobial treatment
as an independent determinant of hospital mortality. To assess
the importance of inappropriate initial antimicrobial treatment
in potential intermediate variables and confounding variables,
two subgroup analyses were performed. Among the 198 pa-
TABLE 2. Specific organ dysfunction and secondary outcomes
Variable Survivors (n  241) Nonsurvivors (n  64) P value
Circulatory shock requiring
vasopressors, n (%)
63 (26.1) 45 (70.3) 0.001
Respiratory failure, n (%) 62 (25.7) 45 (70.3) 0.001
Acute renal failure, n (%) 24 (10.0) 18 (28.1) 0.001
Subsequent bacteremia, n (%) 16 (6.6) 7 (10.9) 0.247
Hospital length of stay, daysa 23.9  29.1 (14.0, 4.25–23.75) 44.5 40.8 (27.5, 11.375–43.625) 0.001
a Values are presented as mean  SD (median, interquartile range).
TABLE 3. Antimicrobial susceptibility of P. aeruginosa bloodstream isolates (n  305)a
Antimicrobial(s)
% Susceptible in:
1997 (n  52) 1998 (n  53) 1999 (n  53) 2000 (n  50) 2001 (n  50) 2002 (n  47) All years
Cefepime NFb 93.8 90.6 94.0 92.1 91.5 92.3
Ceftazidime 96.1 92.3 NF NF NF NF 94.0
Piperacillin-tazobactam NF 96.9 92.5 92.0 94.7 91.5 93.7
Imipenem-cilastatin 88.5 89.2 94.3 88.0 84.2 78.7 87.5
Ciprofloxacin 88.5 80.0 83.0 78.0 68.4 78.7 80.0
Gentamicin 92.3 90.8 92.5 92.0 92.1 100.0 93.1
Tobramycin 94.2 96.9 92.5 94.0 97.4 100.0 95.7
a Resistance to antimicrobial combinations: cefepime or ceftazidime and aminoglycoside, 2.3%; cefepime or ceftazidime and ciprofloxacin, 4.6%; piperacillin-
tazobactam and aminoglycoside, 1.6%; piperacillin-tazobactam and ciprofloxacin, 4%; imipenem-cilastatin and aminoglycoside, 2.3%; imipenem-cilastatin and cipro-
floxacin, 5.6%.
b NF, nonformulary.
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tients without respiratory failure, inappropriate initial antimi-
crobial treatment (n  43) was associated with a statistically
greater hospital mortality compared to appropriate initial an-
timicrobial treatment (n  155) (18.6% versus 7.1%; P 
0.023). Similarly, among the 197 patients without circulatory
shock, inappropriate initial antimicrobial treatment (n  42)
was associated with a greater hospital mortality compared with
appropriate initial antimicrobial treatment (n  155) (16.7%
versus 7.7%; P  0.082).
Secondary outcomes. Hospital nonsurvivors had statistically
longer hospital lengths of stay than hospital survivors (Table
2). Similarly, patients receiving inappropriate initial antimicro-
bial treatment had statistically longer hospital lengths of stay
than those receiving appropriate treatment (41.4  47.4 days
versus 23.9  25.2 days; P  0.006). Among the hospital
survivors, those receiving inappropriate initial antimicrobial
treatment (n  52) had a trend towards longer hospital length
of stay compared to patients receiving appropriate treatment
(n  189) (34.0  44.4 days versus 21.1  22.6 days; P 
0.096).
DISCUSSION
Our study demonstrated that inappropriate initial antimicro-
bial treatment of P. aeruginosa bloodstream infection is asso-
ciated with statistically greater mortality compared to initial
treatment with an antimicrobial regimen to which the bacteria
were susceptible. Multiple logistic regression analysis identi-
fied inappropriate initial antimicrobial treatment as an inde-
pendent predictor for hospital mortality. Additionally, our data
showed that initial treatment with combination antimicrobial
agents directed against P. aeruginosa was statistically more
likely to provide appropriate treatment than was monotherapy.
Finally, the use of fluoroquinolone antibiotics was associated
with a statistically greater likelihood of inappropriate initial
treatment, while cefepime and ceftazidime were statistically
more likely to be associated with appropriate therapy.
Previous investigations have shown that antimicrobial regi-
mens lacking activity against identified microorganisms causing
serious infections (e.g., hospital-acquired pneumonia, blood-
stream infections) are associated with greater hospital mortal-
ity (15, 17, 19). More recently, the same finding has been
demonstrated for patients with severe sepsis (8, 10, 14). Inap-
propriate antimicrobial treatment has been shown to be an
important independent risk factor for mortality among hospi-
talized patients with bloodstream infections (15). Unfortu-
nately, changing antimicrobial therapy to an appropriate reg-
imen after susceptibility data become available has not been
demonstrated to improve clinical outcome (20, 28). These
studies suggest that clinicians should strive to administer ap-
propriate initial antimicrobial treatment for patients with seri-
ous infections, including P. aeruginosa bloodstream infections.
In addition to selecting an appropriate initial antimicrobial
regimen, optimal dosing, interval of drug administration, and
duration of treatment are required for antimicrobial efficacy,
limiting toxicity, and to prevent the emergence of bacterial
resistance (18).
This study is unique in having a relatively large population of
patients with P. aeruginosa bloodstream infection for evalua-
tion. Bryan et al. previously found that appropriate antimicro-
bial therapy for gram-negative bacteremia, on the calendar day
the blood culture was identified to be positive, was not associ-
ated with improved survival (4). Appropriate antibiotic treat-
ment subsequent to the first calendar day on which blood
cultures were positive did favorably appear to influence out-
comes. Vidal et al. were only able to demonstrate an associa-
tion between inappropriate definitive antimicrobial treatment
for P. aeruginosa bacteremia and mortality after excluding the
subset of patients with catheter-associated bloodstream infec-
tion from their analysis (32). Similarly, Chatzinikolaou et al.
did not find a relationship between the appropriateness of
antibiotic treatment and mortality among cancer patients with
P. aeruginosa infection (6).
Bodey et al. examined 410 episodes of Pseudomonas bacte-
remia and found that patients receiving appropriate antibiotic
therapy had a greater likelihood of achieving a clinical cure of
their infection (3). This same group of investigators showed
that patients treated with a beta-lactam antibiotic with or with-
out an aminoglycoside had a significantly higher cure rate than
patients who received only an aminoglycoside (3). Similarly,
Chamot and coworkers demonstrated that patients with
Pseudomonas bacteremia treated with combination empirical
antimicrobial therapy until receipt of the antibiogram had a
better 30-day survival compared to monotherapy (5). However,
combination antimicrobial therapy given as definitive treat-
ment for P. aeruginosa bacteremia did not improve the rate of
survival compared to appropriate definitive monotherapy (5).
Our study results are consistent with the findings from these
two investigations. We showed that initial appropriate antimi-
crobial treatment for P. aeruginosa bacteremia can improve










Cefepime 141 (61.3) 33 (44.0) 0.009
Ceftazidime 36 (15.7) 3 (4.0) 0.009
Piperacillin-tazobactam 5 (2.2) 3 (4.0) 0.686
Imipenem 31 (13.5) 9 (12.0) 0.742
Aminoglycosideb 102 (44.3) 30 (40.0) 0.509
Ciprofloxacin 32 (13.9) 19 (25.3) 0.021
Aztreonam 1 (0.4) 0 (0.0) 0.999
Other 4 (1.7) 2 (2.7) 0.638
a Appropriate antimicrobial treatment was defined as in vitro susceptibility
testing demonstrating a sensitive isolate of P. aeruginosa to the antimicrobial
agent prescribed.
b Includes gentamicin, tobramycin, and amikacin.
TABLE 5. Multivariate analysis of independent risk factors for
hospital mortalitya




Respiratory failure 5.18 3.30–8.13 0.001
Circulatory shock 4.00 2.71–5.91 0001
a CI, confidence interval. Note: other covariates not presented in the table had
a P value of 0.05, including race, infection source, acute renal failure, patient
location, and SAP score. Hosmer-Lemeshow deciles of risk statistic, P  0.33.
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outcome and that combination antimicrobial therapy may be
superior to monotherapy for initial empirical treatment but not
for definitive therapy after the antibiogram results are known.
A potential explanation for the discordant findings among
the studies of P. aeruginosa bloodstream infection is how ap-
propriate antimicrobial treatment was defined. In at least one
of the prior studies, appropriate antimicrobial treatment was
defined according to the initial drug class selection and not on
the basis of in vitro susceptibility testing (6). This definition
would classify patients as receiving appropriate initial treat-
ment despite the presence of a P. aeruginosa isolate resistant to
the prescribed antibiotic(s). In a pediatric study of Pseudomo-
nas bacteremia, antimicrobial susceptibility was not identified
as a prognostic factor (12). However, the administration of
appropriate treatment was not specifically examined. This in-
vestigation did find that prior antibiotic administration was
associated with greater patient mortality. Interestingly, prior
antibiotic treatment has consistently been demonstrated to be
a risk factor for subsequent infection with antibiotic-resistant
bacteria, including P. aeruginosa, and the subsequent adminis-
tration of inappropriate antimicrobial treatment (9, 15, 19).
Harbarth et al. examined 224 episodes of bloodstream in-
fection among patients admitted to a surgical intensive care
unit (13). They found that appropriate antimicrobial therapy
was an independent determinant of survival and that mortality
rates were highest for pathogens most likely to be treated with
inappropriate initial antimicrobial regimens (Candida species,
Enterobacter species, and P. aeruginosa). Similarly, we previ-
ously showed that there is a statistically significant correlation
between the rates of inappropriate antimicrobial treatment for
individual microorganisms causing bloodstream infection and
their associated hospital mortality (15). Three recent studies of
patients with severe sepsis, many of whom had bloodstream
infections, also demonstrated that inappropriate initial antimi-
crobial therapy was associated with greater hospital mortality
(8, 10, 14). These investigations support the importance of
early administration of appropriate antibiotics to patients with
serious infections, including bloodstream infection (22).
A potential advantage of combination antimicrobial therapy
over monotherapy is the higher probability that the infecting
pathogen will be covered by at least one of the components of
the regimen. Furthermore, an interaction between two antibi-
otics may be synergistic, resulting in enhanced bacterial kill
activity compared to the additive activities of the antibiotics
when assessed separately (11). Finally, use of combination
therapy has been claimed to suppress emergence of resistant
subpopulations of bacteria (34). On the other hand, benefits of
monotherapy may include lower costs, fewer adverse effects,
especially when aminoglycosides are avoided, and a narrower
spectrum of treatment, possibly reducing the chance of devel-
oping a superinfection with resistant bacteria. Two recent
meta-analyses have concluded that patients with neutropenic
fever and severe sepsis should be treated with empirical mono-
therapy for presumed infection attributed to gram-negative
bacteria, due to fewer adverse effects linked to the antimicro-
bial treatment (26, 27). Most of the adverse events identified in
these analyses were associated with the use of aminoglycosides.
Unfortunately, these analyses did not evaluate the importance
of appropriate initial antimicrobial treatment and examined
small numbers of patients with microbiologically documented
infections due to P. aeruginosa. The results from our investi-
gation differ, suggesting that patients with P. aeruginosa blood-
stream infection may benefit from the initial administration of
combination antibiotic treatment.
Our study has several important limitations. First, we did not
identify risk factors for the presence of P. aeruginosa blood-
stream infection. Earlier reports have demonstrated that pro-
longed hospitalization, prior treatment with antibiotics, partic-
ularly broad-spectrum antibiotics, and colonization with P.
aeruginosa increase the likelihood of infection with this patho-
gen (9, 18, 31). The presence of such risk factors has been
advocated as a trigger for the empirical treatment of poten-
tially antibiotic-resistant bacteria (31). Second, our study was
performed at a single site and the results may not be applicable
to other settings. However, the consistent relationship demon-
strated between inappropriate treatment of serious bacterial
infections and outcome suggests that this is a more universal
finding (17). Third, we did not attempt to directly control the
antimicrobial treatment prescribed to patients. It is possible
that our results would have varied if more rigid antimicrobial
control policies were in place. Nevertheless, only nine (3.0%)
patients were treated initially with antimicrobial agents lacking
potential activity against P. aeruginosa. This was most likely
related to the overall prevalence of P. aeruginosa as a pathogen
in our hospital and the empirical antimicrobial protocols em-
phasizing the local use of antipseudomonal beta-lactam anti-
biotics. The greater mortality observed among patients not
included in our analysis due to missing data also suggests the
potential for a reporting bias in our results. Finally, due to the
observational design of this study, a definitive relationship be-
tween the use of combination antimicrobial therapy and im-
proved administration of appropriate treatment for P. aerugi-
nosa bloodstream infections cannot be inferred.
In summary, we demonstrated that appropriate initial anti-
microbial treatment for P. aeruginosa bloodstream infection
was associated with statistically greater hospital survival. Ad-
ditionally, the initial empirical use of combination antimicro-
bial therapy directed against gram-negative bacteria was asso-
ciated with greater administration of appropriate treatment.
The majority of inappropriate initial antimicrobial treatment
was the consequence of drug resistance, despite promoting
empirical antibiotic regimens with agents having potential ac-
tivity against P. aeruginosa. This underscores the clinical im-
portance of escalating antimicrobial resistance among bacterial
pathogens. Future studies are needed to define the optimal
strategy for the empirical treatment of patients at risk for P.
aeruginosa bloodstream infection. Until such data become
available, clinicians may consider the use of empirical combi-
nation antimicrobial treatment for such patients, balancing this
against the potential for greater toxicity and the emergence of
antimicrobial resistance.
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